Skye Bioscience Reports Third Quarter 2025 Financial Results and Business Update

Core Insights - Skye Bioscience, Inc. is focused on developing nimacimab, a molecule aimed at treating obesity and related conditions, with promising results from its Phase 2a clinical trial [1][2][12] Financial Results - For Q3 2025, Skye reported a net loss of $12.8 million, with R&D expenses increasing to $9.4 million from $4.9 million in Q3 2024, primarily due to clinical trial costs and contract manufacturing [10][8] - General and administrative expenses decreased to $3.9 million from $4.6 million in the same period last year [9] - Cash and cash equivalents totaled $35.3 million as of September 30, 2025, expected to fund operations into 2027 [7] Clinical Trial Highlights - The topline data from the CBeyond Phase 2a study showed a 29% relative increase in weight loss for the nimacimab/semaglutide combination compared to semaglutide alone after 26 weeks [6] - The combination therapy also resulted in a significant reduction in waist circumference by 3.2 cm compared to semaglutide alone [6] - Rebound weight gain was lower in the combination group, with 18.1% weight regained compared to 49.8% in the semaglutide-only group over 12 weeks post-treatment [6] Upcoming Milestones - Skye has completed enrollment for a 26-week extension study with 43 patients, and data is expected in Q1 2026 [6] - The company is shifting focus to a combination development pathway while also exploring nimacimab's potential as a monotherapy [2]